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In the disease familial amyloidosis, Finnish type (FAF), also known
as AGel amyloidosis (AGel), the mechanism by which point
mutations in the calcium-regulated actin-severing protein gelsolin
lead to furin cleavage is not understood in the intact protein. Here,
we provide a structural and biochemical characterization of the
FAF variants. X-ray crystallography structures of the FAF mutant
gelsolins demonstrate that the mutations do not significantly
disrupt the calcium-free conformations of gelsolin. Small-angle
X-ray–scattering (SAXS) studies indicate that the FAF calcium-
binding site mutants are slower to activate, whereas G167R is as
efficient as the wild type. Actin-regulating studies of the gelsolins
at the furin cleavage pH (6.5) show that the mutant gelsolins are
functional, suggesting that they also adopt relatively normal ac-
tive conformations. Deletion of gelsolin domains leads to sensiti-
zation to furin cleavage, and nanobody-binding protects against
furin cleavage. These data indicate instability in the second do-
main of gelsolin (G2), since loss or gain of G2-stabilizing interac-
tions impacts the efficiency of cleavage by furin. To demonstrate
this principle, we engineered non-FAF mutations in G3 that disrupt
the G2-G3 interface in the calcium-activated structure. These mu-
tants led to increased furin cleavage. We carried out molecular
dynamics (MD) simulations on the FAF and non-FAF mutant G2-
G3 fragments of gelsolin. All mutants showed an increase in the
distance between the center of masses of the 2 domains (G2 and
G3). Since G3 covers the furin cleavage site on G2 in calcium-
activated gelsolin, this suggests that destabilization of this inter-
face is a critical step in cleavage.
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Familial amyloidosis, Finnish type (FAF), also known as AGelamyloidosis (AGel), is an autosomal-dominant and mono-
genic disease characterized by deposition of amyloid fibrils de-
rived from the gelsolin protein in different organs and tissues.
Symptoms include corneal lattice dystrophy, cranial neuropathy,
skin elasticity problems, and renal complications (1–3). It was
first described to be restricted to the Finnish population (4), but
more recently, cases have been reported with known and novel
mutations in individuals with genetic backgrounds from Africa,
Asia, Europe, and South America (5–11). Most mutations known
to cause gelsolin amyloidosis arise from a single-point mutation in
exon 4 (G167R, N184K, and D187N/Y; mature plasma gelsolin
numbering here and throughout the manuscript) (12–14). Recently,
3 new mutations were reported P432R, A551P, and one in exon 1,
causing a frameshift in the gelsolin gene (Ala7fs) (11, 15–17).
The most common FAF mutation, D187N/Y (substitution of
aspartic acid 187 to asparagine or tyrosine), occurs in the
Ca2+ binding site of the second domain of gelsolin (G2), which
prevents calcium binding to G2 (18–20). Therefore, disruption of
the conformational changes of gelsolin upon calcium activation
is thought to be aberrant, and G2 becomes unstable in the
presence of these mutations (19, 21–23). Under these conditions,
gelsolin becomes activated, but transformation from the closed
inactive conformation to the open active conformation is likely
to be less efficient (20). Another distinct gelsolin mutant involves
the substitution of glycine to arginine at position 167 (G167R), a
mutation that is not in a calcium-binding residue. This mutation
has been proposed to cause domain-swapped aggregation (24).
The various point mutations lead to partially misfolded protease-
sensitive products (25), which are targeted when the proteins
travel through the trans-Golgi network during secretion. There,
the mutant gelsolins are cleaved by furin, and a C-terminal 68-
kDa fragment (C68) is produced. This truncated fragment of
gelsolin is then degraded by the membrane type 1 matrix met-
alloprotease on export outside the cell, giving rise to 8- and
5-kDa amyloidogenic fragments, which self-assemble (26). The
frameshift mutation (Ala7fs) would not be expected to translate
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the region of gelsolin to form FAF fragments (11), thus any
amyloids formed from the Ala7fs mutation likely have a distinct
composition relative to the other FAF fibrils.
We previously investigated the inactive and active conforma-
tions of wild-type (WT) gelsolin (27). Here, we assess the impact
of the FAF mutations on the gelsolin structure using X-ray crys-
tallography, small-angle X-ray scattering (SAXS), biochemical
assays, and furin cleavage assays. We find that these mutations
disrupt the dynamics of domain:domain interactions with G2 and
lead to sensitization to furin cleavage. By contrast, the allosteric
binding of a nanobody to G2 protects against furin cleavage.
Together, these data suggest that G2 is close to the limit of sta-
bility and that multiple modifications are capable of shifting the
balance toward instability.
Results
To understand the structural basis of the breakdown of gelsolin
in FAF, we crystallized and solved the calcium-free X-ray struc-
tures of the FAF mutant gelsolins G167R, D187N, and D187Y
(28–30). These mutants crystallized in the wild-type crystallization
conditions and formed crystals of the same space group and similar
cell dimensions. Molecular replacement using the wild-type struc-
ture led to structures of the mutants that showed no gross con-
formational changes with respect to the wild-type structure (Fig. 1),
characterized by RMSDs of 0.41–0.51 Å in comparison with the
wild-type structure (Fig. 1F). The mainchain electron density
around the mutation sites was well defined with reasonable density
for the mutant sidechains (Fig. 1 A–E), indicating that the muta-
tions do not induce large changes in the calcium-free gelsolin
structure. Closer examination of the mutation conformations
revealed differences in the bonding patterns of the mutant resi-
dues. Wild-type Asp187 is able to form a charge–charge interac-
tion with Lys166 and 2 potential hydrogen bonds with Asn184 and
Gln164, interactions that stabilize the G2 β-sheet (SI Appendix,
Fig. S1). The D187N mutant loses the ability to form the charge–
charge interaction but can form potential hydrogen bonds with
Gln164, Lys166, and Asn184 (SI Appendix, Fig. S1A). D187Y is
unable to form charge–charge interactions or hydrogen bonds with
these residues (SI Appendix, Fig. S1B). By contrast, in the absence
of a sidechain in wild-type Gly167, there is no loss of bonding
pattern on mutation. However, the bulkier arginine residue ap-
proaches G3 (SI Appendix, Fig. S1C) and may pay a steric penalty.
Furthermore, the sidechains around 167Arg show differences
between the 2 copies in the asymmetric unit in this region. This
indicates that loss of mainchain rotational freedom, in replacing
glycine by arginine, and the difficulty in accommodating the
bulkier residue, impacts on the mainchain conformation. The
following residues, Arg168 and Arg169, form charge–charge in-
teractions with Asp669 and Asp670, respectively, which are a major
determinant of the G2:G6 interaction that locks the calcium-free
Fig. 1. Schematic representation of the structure of
full-length gelsolin. Figure is colored with domain
G1 in red, domain G2 in light green, domain G3 in
yellow, domain G4 in purple, domain G5 in dark
green, and domain G6 in orange (Center). The black
square focuses on the FAF mutation region of do-
main G2. The 2Fo-Fc electron density map of the
residues is shown as a gray grid comparing the 3
different mutants contoured at 1 σ, with (A) Asn187,
(B) Native Asp187, (C) Tyr187, (D) Native Gly167, and
(E) Arg167. Mutated residues are highlighted with a
red star. (F) Comparison of the root-mean-square
deviation values of the native gelsolin structure
versus mutants.








































structure (27). Any disruption to this interaction would be
predicted to reduce the stability of the inactive conformation.
Thus, the calcium-free structures display the normal gelsolin
conformation, but may be dynamically less stable.
Next, we asked whether the mutant gelsolins are functional at
pH 6.5, the pH of the trans-Golgi. In a pyrene–actin polymeri-
zation assay the mutant gelsolins, in the presence of calcium,
were able to overcome the lag phase in actin polymerization,
caused by the slow rate of the nucleation step of actin poly-
merization (Fig. 2A). This suggests that the mutants can be ac-
tivated by calcium and bind to 2 actin monomers in an F-actin
conformation that allows pointed end elongation. Furthermore,
in an actin filament sedimentation assay the mutant gelsolins
were able change the location of actin from the pellet to the
supernatant on the addition of calcium (Fig. 2 B–E). This activity
is consistent with the mutant gelsolins retaining their ability to
undergo calcium-induced conformational changes to sever actin
filaments. Thus, the active conformations of the FAF gelsolins
appear to be normal by using biochemical activity as a proxy for
assessing the ability to reach the active calcium-bound structure.
Since the D187N/Y mutations involve a type II calcium-
binding site in G2 (31) we followed the global calcium-induced
conformational changes in the gelsolins using time-resolved
SAXS. For the wild-type protein, a clear conformational change
was observed in the Kratky plots and in changing the radius of
gyration (Rg) on adding calcium, and this change was close to
completion at the first recordable time point (130 ms) measure-
ment after the addition of calcium (Fig. 3 A and E). The calcium-
binding site mutants showed delayed conformational changes.
D187Y achieved the conformational change in the timeframe of
the experiment (400 ms, Fig. 3 B and E), whereas D187N showed
only partial conformational change within this timeframe (Fig. 3 C
and E). Finally, the G167R mutant activated on the same time-
scale as the wild-type protein (Fig. 3 D and E). Thus, mutations
to the G2 calcium-binding site result in lower efficiency in the
calcium-induced conformational changes.
The stability of the calcium-free and calcium-bound structures
was assessed using a thermal denaturation assay. In the absence
of calcium, the G167R mutant was ∼4° less stable than the wild-
type and the D187N/Y mutants (Fig. 3F), which had midpoints
to their thermal denaturation transition profiles of ∼54 °C. The
reduced G167R mutant stability may be attributed to the sub-
optimal interactions between G2 and G6, as discussed for the
calcium-free crystal structure above. Addition of calcium in-
creased the stability of all of the proteins, characterized by
midpoints in their thermal denaturation profiles of ∼60 °C (Fig.
3G). This suggests that the final calcium-activated structures are
similar for wild-type and mutant gelsolins. Taken together, these
data indicate that the mutant proteins can adopt similar inactive
and active structures to the wild-type proteins and that they are
functional in regulating actin. However, the D187N/Y mutants
show slightly delayed calcium activation, and the G167R mutant
shows lower stability in its inactive form.
Next, we turned to a furin cleavage assay to understand how
these minor differences translate into different biological outcomes.
All 3 mutants, but not the wild type, showed cleavage by furin at pH
6.5, the approximate pH of the trans-Golgi (Fig. 4A). This effect
was diminished in the presence of a nanobody (Nb11) that binds to
G2 at a site that is distant from the furin cleavage site (Fig. 4A) (32).
The furin cleavage became more robust under the same conditions
when a fragment, comprised of domains 2 and 3 (G2G3), of gelsolin
was used (Fig. 4B). The wild-type G2G3 remained intact, whereas
the mutants were completely cleaved, and the nanobody afforded
almost complete protection against cleavage.
We hypothesized that the interaction between domains G2
and G3 may be important in protecting G2 from cleavage. To
test this hypothesis, we created mutations in G3 that would be
predicted to disrupt the active structure of G2G3 (SI Appendix,
Fig. S2). These mutants were subjected to the furin cleavage
assay (Fig. 4C). All 3 non-FAF mutants (K314M, L361D, and
Q364L) were able to induce susceptibility to furin cleavage, and
total protection from furin cleavage was imparted by the inclusion
of the nanobody, despite it binding to the other domain (G2)
rather than to the domain with mutation sites (G3) (Fig. 4D).
To understand the impact of these mutations on the gelsolin
structure, we performed molecular dynamics (MD) simulations
for the wild type, the FAF mutant, and the non-FAF G2G3 mu-
tants. All of the mutations tend to disrupt the G2G3 structure as
indicated by the increase of the overall root-mean-square de-
viation (RMSD) from the starting structures and the center of
mass (COM) distances between the 2 domains (Fig. 5 and SI
Appendix, Figs. S5–S7). The structure disruption effect can also be
observed from the potentials of mean force, which show that the
free-energy penalties of separating the domains G2 and G3 are
significantly reduced in all of the mutants (Fig. 5B and SI Ap-
pendix, Fig. S5B). More detailed analysis suggests that the muta-
tions mainly disrupt the G2-G3 interface, and the structures of the
individual domains mostly remain intact through the timescale
Fig. 2. FAF gelsolin activity at pH 6.5. (A) Actin nucleation assay with FAF
gelsolin mutants. G-actin was incubated with different gelsolin mutants at a
molar ratio of 1:100 for 1 h followed by the addition of 10× KMEI buffer. FAF
mutants nucleate actin filaments similarly as wild-type gelsolin. Data rep-
resent the average of 3 experiments. (B–E) FAF gelsolins sever F-actin. Sed-
imentation assays of FAF gelsolin were carried out under EGTA and calcium
conditions. F-actin was incubated with different concentrations of wild-type
and mutant gelsolins for 1 h at room temperature and subjected to ultra-
centrifugation, and the supernatants (S) and pellets (P) were analyzed by
SDS/PAGE. (B) WT, (C) 187N, (D) 187Y, (E) 167R. Right, 1.5 mM EGTA. Left,
1 mM calcium chloride.

































(150 ns) of the simulations (SI Appendix, Figs. S8 and S9). The
above observations are consistent with the results of the furin
cleavage assay, since G3 covers the furin-cleavage site on G2 in the
calcium-bound conformation (21), and the disruption of the G2-
G3 interface by mutation makes the site accessible to furin.
Discussion
We have probed the effect of FAF mutations on the structure
and activity of full-length gelsolin. The FAF mutations have
minimal impact on the structure of gelsolin and have little con-
sequence on its activity. The calcium-binding site mutations delay
calcium-induced activation, while the G167R mutation destabilizes
the inactive conformation. Removal of domains G1 and G4-G6
results in a fragment of gelsolin (G2G3) that is sensitized to furin
cleavage. This suggests that the removed domains contribute to the
stability of G2 and impart partial protection from cleavage by furin
to the FAF mutant gelsolins. Similarly, binding of a nanobody to
G2, to a distant site to the furin-cleavage site, also engenders pro-
tection. These data all point toward the conformation of G2 to be
close to the limits of stability (19, 32). A second factor in de-
termining susceptibility to cleavage is the accessibility of the furin
cleavage site. Loss of interactions with residue 187 or introduction
of a steric handicap (G167R) lead to the domain sampling of
conformations that can be cleaved by furin. In calcium-bound G2G3
this site on G2 is occluded by G3. The non-FAF mutants dem-
onstrated that disruption of this interface results in increased
cleavage. Dissociation of G3 will simultaneously have an impact
on the stability of G2, due to the loss of this stabilizing interaction.
Inspection of the activated structure of G1-G3 reveals that each of
the FAF mutations in domain 2 (G167R, N184K, and D187N/Y)
will directly impact the ability for G3 to cover the FAF-cleavage
site on G2 (27). D187N/Y mutants disrupt the calcium-binding
site, which holds the G2-G3 linker in place, while G167R and
N184K point their sidechains at the G2-G3 linker, likely per-
turbing the positioning of the linker and destabilizing the G2:G3
interaction. We note that the P432R and A551P mutation sites lie
at positions in both the calcium-free and calcium-bound confor-
mations of gelsolin that may be expected to disrupt the G4:G5
interface. Thus, these mutants may disrupt the general structure
of gelsolin, and since G3 is linked to G4, any disruption to the
G4:G5 may have knock-on effects for the dynamics of the G2:G3
interaction and sensitize G2 to cleavage. We conclude that G2 is
quasi-stable, and any perturbation that decreases the stability of
G2 and disrupts the G2:G3 interaction leads to exposure of the
furin cleavage site, resulting in the fragmentation of the protein.
This mechanism predicts that there are further mutations to
gelsolin, such as the non-FAF mutants created here, that can in-
crease the susceptibility of the gelsolin to cleavage by furin. Should
such variants be present in the human population, then the mecha-
nism also predicts that these mutant gelsolins will be cleaved in
the trans-Golgi, and that the carriers may exhibit FAF symptoms,
following further extracellular cleavage and self-assembly of the
resultant peptides into fibrils.
Materials and Methods
Constructs and Protein Production. DNA encoding full-length human gelsolin
(residues 25–755) and G2-G3 (residues 132–372) was engineered into the ex-
pression vector pSY5, a modified version of pET-21d(+) (Novagen), which
places an N-terminal, 8-histidine tag, followed by a human rhinovirus 3C
protease cleavage site ahead of the N termini of the proteins. Mutated vari-
ants of full-length gelsolin (D187N/Y and G167R) were constructed by using
QuikChange site-directed mutagenesis (Stratagene) with the full-length wild-
type gelsolin and G2-G3 as the templates. DNA sequencing verified the iden-
tities of the constructs. Recombinant proteins were expressed and purified as
described previously (27). The oligomeric states of the full-length proteins were
analyzed by size exclusion chromatography (SEC) monitored by UV absorption
and multiangle light scattering (MALS), which gave profiles consistent with
monomeric proteins with estimated molecular weights between 67–80 kDa for
these 83-kDa proteins (SI Appendix, Fig. S10). Nanobody Nb11 was purified as
previously reported (32).
Size Exclusion Chromatography–Multiangle Light Scattering. DAWN HELEOS 8
multiangle light-scattering 3-angle (43.6°, 90°, and 136.4°) detector and a
663-nm laser beam, with a Wyatt QELS dynamic light-scattering module for
determination of molecular size and an Optilab T-rEX refractometer, were
used after size exclusion chromatography (Superdex 200 10/300 GL, GE
Healthcare). Experiments were performed using an ÄKTA explorer system
(GE Healthcare). All experiments were performed at room temperature
(25 °C). Data collection and SEC-MALS analysis were performed with ASTRA
6.1 software (Wyatt Technology). The refractive index of the solvent was
defined as 1.331, and the viscosity was defined as 0.8945 cP. The dn/dc (re-
fractive index increment) value for all samples was defined as 0.185 mL/g.
For SEC-MALS experiments, 100 μL of 10 mg/mL gelsolin proteins were
loaded on a Superdex 200 column with running buffer of 50 mM Tris·HCl, pH
7.4, and 150 mM NaCl.
Crystallization and Data Collection. Crystals of Ca-free GFL mutants (D187N,
D187Y, and G167R) were obtained after mixing 18 mg/mL solution of protein
with precipitant solution (15% glycerol, 1.5 M ammonium sulfate, and 0.1 M
Tris·HCl, pH 8.5) at 25 °C by using the hanging-drop vapor diffusion method.
The crystals were frozen in liquid nitrogen after soaking in the precipitant
solution supplemented with 20% glycerol. X-ray diffraction data were col-
lected on beamline BL13B1 on an Area Detection Systems Corporation
Quantum-315 CCD detector at the National Synchrotron Research Center
(Hsinchu, Taiwan). The wavelength was set to 1 Å, and the data were col-
lected at 105 K. D187N mutant data were collected on beamline I02 on
Fig. 3. Kratky plots of the time points of calcium ac-
tivation of (A) WT, (B) D187Y, (C) D187N, and (D) G167R
gelsolins. In all panels, the individual frames of the
stopped-flow experiments, with 4 mg/mL protein in the
presence of 1 mM Ca2+ are shown color-coded from
blue (130ms) to red (400ms) for increasing time points.
For theWT gelsolin, steady state continuous flow plots
are included, EGTA (solid black line) and calcium
(dashed black line). For reference, these WT contin-
uous flow profiles are also shown as gray lines in the
mutant panels. (E) Time dependence of Rg values. (F
and G) Thermal shift assays. Thermal denaturation
studies of WT and mutants in the presence of EGTA
(F) or calcium chloride (G). Values of the midpoints
of the WT thermal denaturation profiles are indicated.








































Pilatus 6MF detector at the Diamond Light Source. Data were indexed, in-
tegrated, and scaled using HKL2000 (33) or xia2 (34). Crystal structures were
solved by molecular replacement using human Ca-free gelsolin as the search
model (PDB 3FFN) (27, 35). The structures were refined using REFMAC5 (36)
or Phaser (35). Manual building was made using the graphics program COOT
(37). Data collection and refinement statistics are shown in SI Appendix,
Table S1.
Actin Nucleation Assay. Ten percent pyrene-labeled G-actin (2 μM) was in-
cubated with the respective gelsolin protein at a molar ratio of 1:100 in
buffer A (2 mM Tris·HCl, pH 8, 0.2 mM ATP, 0.1 mM CaCl2, 0.5 mM DTT, 1 mM
Na azide) in a final volume of 90 μL for 30 min in 96-well black flat-bottomed
plates (Corning). Ten microliters of 10× polymerization buffer (500 mM
KCl, 10 mM MgCl2, 10 mM EGTA (ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid), 100 mM imidazole HCl, pH 7) was added to each
reaction before measurement of the fluorescence intensity at excitation and
emission wavelengths of 365 and 407 nm, respectively, with a Safire2
fluorimeter (TECAN).
Thermal Shift Assays. The reaction mixture, consisting of 12.5 μL of (20 mM
Hepes, 100 mM NaCl, pH 6.5) buffer with either 1 mM CaCl2 or 1 mM EGTA,
5 μL of 2.5 mg/mL protein, and 7.5 μL of 100× Sypro orange (Molecular Probes),
was added to each well in 96-well PCR plates (BioRad). Plates were sealed and
heated with a temperature range from 20 °C to 80 °C in 0.2 °C increments in
an iCycler iQ Real-Time PCR Detection System (BioRad). The transition tem-
perature of each protein was determined as described previously (38).
Furin Assays. Gelsolin (5 mM) was incubated at 37 °C with 1 unit of furin
(New England Biolabs) in 20 mM MES (2-(N-morpholino)ethanesulfonic
acid) pH 6.5, 100 mM NaCl, 1 mM CaCl2. After 60 min incubation, reactions
were quenched by the addition of EGTA (100 mM) on ice. The proteolysis
reaction was monitored by SDS/PAGE. The extent of cleavage was assessed
by densitometry as the average value from 3 gels.
Actin Sedimentation Assay. Gelsolin WT and mutants were tested for their
ability to bind F-actin under both calcium and EGTA conditions. Various con-
centrations of the protein were incubated with F-actin in 50 μL of polymerization
buffer for 30 min before centrifugation for 1 h at 150,000 × g using a TLA120.1
rotor in a Beckman Optima Max ultracentrifuge. Fifteen microliters of each
sample (supernatant and pellet) were analyzed by SDS/PAGE.
SAXS Data Acquisition. SAXS data on gelsolin WT and three mutants; D187N,
D187Y, and G167R were collected on beamline ID02 at the European Syn-
chrotron Research Facility (ESRF). The wavelength was set to λ = 1 Å, and the
sample-to-detector (Pilatus 300K) distance was set to either 1.2 or 2.5 m. The
proteins at 8 mg/mL in 50 mM MES, pH 6.5, 150 mM NaCl, 1 mM EGTA were
mixed with an equal volume of 50 mM MES, pH 6.5, 150 mM NaCl, 2 mM
CaCl2 using a stopped flow device (BioLogic, SFM-400). The mixing volume was
0.1 mL, and the mixing time was 95 ms, after which 30 images were recorded
at 10ms per frame. Each experiment was repeated at least 3 times, as were the
matched buffer experiments used for background subtraction. This protocol
was adopted to collect different time frames during the protein activation. To
get a more accurate estimation of the parameters for the starting (EGTA) and
ending (calcium) states for the WT protein, a second set of exposures, in which
the proteins were preequilibrated (30 min) in their final buffer conditions
Fig. 4. Gelsolin FAF mutants are protected by Nb11
from furin cleavage. Susceptibility to furin cleavage
was tested in vitro for both full-length (FL) and G2G3
constructs and analyzed by SDS/PAGE. Incubation of
the (A) FL mutants and (B) G2G3 mutants with furin
for 3 h. Production of cleaved fragments is observed
for the mutants, which is more efficient for G2G3
than FL under the same conditions. Inclusion of Nb11
inhibits the furin cleavage in A and B. “Nb” refers to
the inclusion of nanobody. Below, the extent of
cleavage was assessed by densitometry as the aver-
age value from three gels. (C) Furin cleavage was
tested for the non-FAF G2G3 mutants, which show a
cleaved gel band assessed after 3 h. Inclusion of
Nb11 inhibited the appearance of this gel band.
Time course and titrations for the furin assay are
found in SI Appendix, Figs. S3 and S4. Statistical tests
were applied on differences observed in the per-
centage of cleaved proteins. Data are the average of
three independent experiments ±SD. Student’s t test
(2-sided) was used for statistical analysis. (D) Car-
toons indicate the relative positions of the mutation
sites (stars) relative to G2 (green), G3 (yellow), the
cleavage site (red cross), calcium-binding sites (black
ovals), and the Nb11-binding site.
Fig. 5. Molecular dynamics simulations of the WT and FAF mutants. (A) RMSD of
G2G3 relative to the native structure of the calcium-bound active conformation
(PDB 3FFK) as a function of simulation time. (B) Potential of mean force as a
function of COM distance. The PMF profiles and the errors were calculated by the
averages and SDs of the results from 3 independent umbrella-sampling simulations.

































before being exposed in the continuous flow mode (30 images recorded at
10 ms per frame) and the images averaged together. The final concen-
trations of all protein samples were 4 mg/mL in the presence of 1 mM Ca2+.
SAXS Data Analysis. For each sample, SAXS snapshots were averaged, then
buffer subtracted. SAXS data were analyzed using the ATSAS 2.7.2 software.
To avoid spurious scattering from the beam stop, a minimum threshold of the
scattering angle q = 0.15 nm−1 was used. Before data fitting, time-resolved
measurements at each time point were averaged across experimental repli-
cates, while flow-through experiments were averaged across 30 successive
frames. For all flow-through experiments, the autorg command was used to
automatically determine Rg by Guinier fitting (39). Because the time-resolved
measurements are noisier, manual Guinier fitting was performed with the
PRIMUS graphical user interface (GUI) (40). In all cases, the number of data
points used in the Guinier fit were constrained such that qRg ≤ 1.3. Indirect
Fourier Transform fits were also performed manually (by varying Dmax—the
maximum dimension—and the regularization parameter) using the PRIMUS
GUI. Due to lower signal-to-noise at higher q, only data less than 2 nm−1 were
used for all indirect Fourier Transform fits.
MD Simulations. All-atom MD simulations were performed on the wild-type
G2G3 and its 6 mutants. The initial structure of the wild-type G2G3 was
extracted from the crystal structure of the active conformation of the gelsolin
(PDB 3FFK) (27). The sidechains of the 6 mutants were replaced by using the
software Modeller9 (41). All simulations were carried out using Gromacs 5.1.4
(42) with the CHARMM27 force field for protein and the SPC/E model for water
molecules (43). Cl− and Na+ were added to neutralize the system and to pro-
duce the physiological salt concentration (150 mM). Eight independent simu-
lations with different initial velocities were conducted for each of the systems.
The final simulations were performed in the NPT ensemble at 300 K and 1 atm
with the integration time step of 2 fs. For better characterization of the stability
changes caused by the mutations, we also calculated the potential of mean
force (PMFs) along the separation of the 2 domains for the wild-type G2G3
and its mutants by using umbrella-sampling simulations (44) and the
MBAR reweighting algorithm (45). Fifteen harmonic umbrella potentials
were placed along the distances between the centers of mass of the 2
domains ranging from 25.2 Å to 39.2 Å with the force constant of 20 kJ/
mol/Å2. Each umbrella window was simulated for 20 ns, with the first 10 ns
omitted in the PMF calculations. We repeated the umbrella-sampling
simulations 3 times with different initial structures in the umbrella win-
dows to estimate the errors of the PMFs arising from sampling.
ACKNOWLEDGMENTS. We thank Agency for Science, Technology and
Research (A*STAR) for support and are grateful for the technical services
provided by the National Synchrotron Radiation Research Center (Taiwan),
Diamond Light Source (UK), and The European Synchrotron Radiation
Facility (France).
1. G. Boysen, G. Galassi, Z. Kamieniecka, J. Schlaeger, W. Trojaborg, Familial amyloidosis
with cranial neuropathy and corneal lattice dystrophy. J. Neurol. Neurosurg. Psychi-
atry 42, 1020–1030 (1979).
2. S. Kiuru, E. Matikainen, M. Kupari, M. Haltia, J. Palo, Autonomic nervous system and
cardiac involvement in familial amyloidosis, Finnish type (FAF). J. Neurol. Sci. 126, 40–
48 (1994).
3. C. P. Maury, J. Kere, R. Tolvanen, A. de la Chapelle, Homozygosity for the Asn187
gelsolin mutation in Finnish-type familial amyloidosis is associated with severe renal
disease. Genomics 13, 902–903 (1992).
4. J. Meretoja, Familial systemic paramyloidosis with lattice dystrophy of the cornea,
progressive cranial neuropathy, skin changes and various internal symptoms. A pre-
viously unrecognized heritable syndrome. Ann. Clin. Res. 1, 314–324 (1969).
5. M. Taira et al., Clinical features and haplotype analysis of newly identified Japanese
patients with gelsolin-related familial amyloidosis of Finnish type. Neurogenetics 13,
237–243 (2012).
6. K. J. Park et al., The first Korean family with hereditary gelsolin amyloidosis caused by
p.D214Y mutation in the GSN gene. Ann. Lab. Med. 36, 259–262 (2016).
7. B. V. Maramattom, Y. T. Chickabasaviah, A new Indian family affected by gelsolin
amyloidosis. Neurol. India 61, 673–675 (2013).
8. F. Lucero Saá, F. A. Cremona, N. X. Mínguez, M. L. Igarzabal, P. Chiaradía, The first
Argentinian family with familial amyloidosis of the Finnish type. Case Rep. Oph-
thalmol. 8, 446–451 (2017).
9. I. Conceição et al., Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese
family: Clinical and neurophysiological studies. Muscle Nerve 28, 715–721 (2003).
10. H. P. Solari, M. P. Ventura, E. Antecka, R. Belfort Junior, M. N. Burnier, Jr, Danish type
gelsolin-related amyloidosis in a Brazilian family: Case reports. Arq. Bras. Oftalmol.
74, 286–288 (2011).
11. X. Feng, H. Zhu, T. Zhao, Y. Hou, J. Liu, A new heterozygous G duplicate in exon1
(c.100dupG) of gelsolin gene causes Finnish gelsolin amyloidosis in a Chinese family.
Brain Behav. 8, e01151 (2018).
12. A. de la Chapelle et al., Gelsolin-derived familial amyloidosis caused by asparagine or
tyrosine substitution for aspartic acid at residue 187. Nat. Genet. 2, 157–160 (1992).
13. S. Sethi et al., Renal amyloidosis associated with a novel sequence variant of gelsolin.
Am. J. Kidney Dis. 61, 161–166 (2013).
14. Y. A. Efebera et al., Novel gelsolin variant as the cause of nephrotic syndrome and
renal amyloidosis in a large kindred. Amyloid 21, 110–112 (2014).
15. K. Z. Oregel et al., Atypical presentation of gelsolin amyloidosis in a man of African
descent with a novel mutation in the gelsolin gene. Am. J. Case Rep. 19, 374–381 (2018).
16. M. Sridharan et al., A patient with hereditary ATTR and a novel AGel p.Ala578Pro
amyloidosis. Mayo Clin. Proc. 93, 1678–1682 (2018).
17. S. Sethi et al., Clinical, biopsy, and mass spectrometry findings of renal gelsolin am-
yloidosis. Kidney Int. 91, 964–971 (2017).
18. S. L. Kazmirski et al., Loss of a metal-binding site in gelsolin leads to familial
amyloidosis-Finnish type. Nat. Struct. Biol. 9, 112–116 (2002).
19. T. Giorgino et al., Nanobody interaction unveils structure, dynamics and proteotox-
icity of the Finnish-type amyloidogenic gelsolin variant. Biochim. Biophys. Acta Mol.
Basis Dis. 1865, 648–660 (2019).
20. C. D. Chen et al., Furin initiates gelsolin familial amyloidosis in the Golgi through a
defect in Ca(2+) stabilization. EMBO J. 20, 6277–6287 (2001).
21. L. D. Burtnick, D. Urosev, E. Irobi, K. Narayan, R. C. Robinson, Structure of the N-
terminal half of gelsolin bound to actin: Roles in severing, apoptosis and FAF.
EMBO J. 23, 2713–2722 (2004).
22. R. C. Robinson, S. Choe, L. D. Burtnick, The disintegration of a molecule: The role of
gelsolin in FAF, familial amyloidosis (Finnish type). Proc. Natl. Acad. Sci. U.S.A. 98,
2117–2118 (2001).
23. A. Srivastava et al., The gelsolin pathogenic D187N mutant exhibits altered conforma-
tional stability and forms amyloidogenic oligomers. Biochemistry 57, 2359–2372 (2018).
24. F. Bonì et al., Gelsolin pathogenic Gly167Arg mutation promotes domain-swap di-
merization of the protein. Hum. Mol. Genet. 27, 53–65 (2018).
25. J. P. Solomon, L. J. Page, W. E. Balch, J. W. Kelly, Gelsolin amyloidosis: Genetics,
biochemistry, pathology and possible strategies for therapeutic intervention. Crit.
Rev. Biochem. Mol. Biol. 47, 282–296 (2012).
26. L. J. Page et al., Metalloendoprotease cleavage triggers gelsolin amyloidogenesis.
EMBO J. 24, 4124–4132 (2005).
27. S. Nag et al., Ca2+ binding by domain 2 plays a critical role in the activation and
stabilization of gelsolin. Proc. Natl. Acad. Sci. U.S.A. 106, 13713–13718 (2009).
28. H. Zorgati et al., Crystal structure of calcium free human gelsolin amyloid mutant G167R.
Protein Data Bank. https://www.rcsb.org/structure/6jeg. Deposited 5 February 2019.
29. H. Zorgati et al., Crystal structure of calcium free human gelsolin amyloid mutant D187N.
Protein Data Bank. https://www.rcsb.org/structure/6jco. Deposited 29 January 2019.
30. H. Zorgati et al., Crystal structure of calcium free human gelsolin amyloidmutant D187Y.
Protein Data Bank. https://www.rcsb.org/structure/6jeh. Deposited 5 February 2019.
31. H. Choe et al., The calcium activation of gelsolin: Insights from the 3A structure of the
G4-G6/actin complex. J. Mol. Biol. 324, 691–702 (2002).
32. W. Van Overbeke et al., An ER-directed gelsolin nanobody targets the first step in
amyloid formation in a gelsolin amyloidosis mouse model. Hum. Mol. Genet. 24,
2492–2507 (2015).
33. Z. Otwinowski, W. Minor, Processing of X-ray diffraction data collected in oscillation
mode. Methods Enzymol. 276, 307–326 (1997).
34. G. Winter, C. M. Lobley, S. M. Prince, Decision making in xia2. Acta Crystallogr. D Biol.
Crystallogr. 69, 1260–1273 (2013).
35. P. D. Adams et al., PHENIX: A comprehensive Python-based system for macromolec-
ular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
36. G. N. Murshudov, A. A. Vagin, E. J. Dodson, Refinement of macromolecular structures
by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255
(1997).
37. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot.
Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
38. M. W. Pantoliano et al., High-density miniaturized thermal shift assays as a general
strategy for drug discovery. J. Biomol. Screen 6, 429–440 (2001).
39. M. V. Petoukhov, D. I. Svergun, Analysis of X-ray and neutron scattering from bio-
macromolecular solutions. Curr. Opin. Struct. Biol. 17, 562–571 (2007).
40. P. V. Konarev, V. V. Volkov, A. V. Sokolova, M. H. J. Koch, D. I. Svergun, PRIMUS: A
Windows PC-based system for small-angle scattering data analysis. J. Appl. Cryst. 36,
1277–1282 (2003).
41. A. Sali, T. L. Blundell, Comparative protein modelling by satisfaction of spatial re-
straints. J. Mol. Biol. 234, 779–815 (1993).
42. M. J. Abraham et al., GROMACS: High performance molecular simulations through
multi-level parallelism from laptops to supercomputers. SoftwareX 1–2, 19–25 (2015).
43. A. D. MacKerell et al., All-atom empirical potential for molecular modeling and dy-
namics studies of proteins. J. Phys. Chem. B 102, 3586–3616 (1998).
44. G. M. Torrie, J. P. Valleau, Nonphysical sampling distributions in Monte Carlo free-
energy estimation: Umbrella sampling. J. Comput. Phys. 23, 187–199 (1977).
45. M. R. Shirts, J. D. Chodera, Statistically optimal analysis of samples from multiple
equilibrium states. J. Chem. Phys. 129, 124105 (2008).
Zorgati et al. PNAS | July 9, 2019 | vol. 116 | no. 28 | 13963
BI
O
CH
EM
IS
TR
Y
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ite
its
bi
bl
io
th
ee
k 
G
en
t o
n 
F
eb
ru
ar
y 
1,
 2
02
0 
